Aula Acreditada:

Información General | Temario | Boletín de inscripción 


 
numero.gif (1368 bytes)


 


 

PROGRAMA ANUAL
2002-2003
DE FORMACIÓN CONTINUADA ACREDITADA
PARA MÉDICOS DE ATENCIÓN PRIMARIA

 

 

  

Insuficiencia Cardiaca Congestiva Crónica en Atención primaria

Bibliografía

- ACC/AHA Guidelines for the Clinical Application of Echocardiography. J Am Coll Cardiol 1997; 29: V1686-1744.
- American Heart Association. Insuficiencia Cardíaca Congestiva. Aspectos clínicos actuales. Barcelona: Medical Trends, SL; 1998.
- Amiodarone Trials Meta-Analysis Investigators. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Lancet 1997; 350: 1417-1424.
- Aronow WS, Kronzon I. Effect of enalapril on congestive heart failure treated with diuretics in elderly patients with prior myocardial infarction and normal left ventricular ejection fraction. Am J Cardiol 1993; 71:602-604.
- Azpitarte J. Los resultados del ensayo RALES constituyen una Buena noticia para los pacientes con insuficiencia cardíaca y... las administraciones sanitarias. Med Clin (Barc) 2000; 114: 545-550.
- Braunwald E, Grossman W. Clinical aspects of heart failure. En: Braunwald E, editor. Heart diseases. A textbook of cardiovacular medicine. Filadelfia: W.B. Saunders, 1992. p. 444-463.
o Burnett J. Reflejo cardiovascular y control humoral de la circulación. En: Revisión en Cardiología de la Mayo Clinic. Barcelona: Medical Trends, SL; 1998. p. 17-19.
- Castro-Beiras A, Crespo MG, Muñiz J. Definición de insuficiencia cardíaca. Epidemiología. En: Ferreira I. Insuficiencia Cardíaca: visión actual. Madrid: Grupo Aula Médica S.A.; 1995. p. 1-16.
- CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353: 9-13.
- Cohn JN, Tognoni G, Glazer RD, Spormann D, Hester A. Rationale and design of the Valsartan Heart Failure Trial: A large multinational trial to assess the effect of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure. J Card Fail 1999; 5: 155-160.
- Cruz JM, López V, Gracia JC, Rojas J. Epidemiología de la Insuficiencia Cardíaca. Rev Esp Cardiol 1997; 50 Supl 3: S4-S10.
- Díaz S, Lobos JM, Conthe P. Insuficiencia cardíaca. Actualización terapéutica. Seguimiento en la consulta de atención primaria. FMC 1997; 2: 75-89.
- Doughty R, Rodgers A, Sharpe N, MacMahon S. Effects of beta-bloquers therapy on mortality in patients with heart failure. Eur Heart J 1997; 18: 560-565.
- Dracup K, Baker DW, Dunbar SB, Dacrey RA, Brooks NH, Johnson JC et al. Tratamiento de la insuficiencia cardíaca. Recomendaciones, educación y modificaciones del estilo de vida. JAMA (ed. esp.) 1995; 4: 368-374.
- Ferreira I, Ferreira A. Modelos conceptuales de la insuficiencia cardíaca. Rev Esp Cardiol 1997; 50 Supl 3: 18-22.
- Francino A, Navarro-López F. Pronóstico del síndrome de la insuficiencia cardíaca. Rev Esp Cardiol 1997; 50 Supl 3: 11-17.
- García M, López-Sendón JL, Navarroz F, Alonso L. Manejo actual de la insuficiencia cardíaca. En: Guías de Actuación Clínica en Cardiología dirigidas a la atención Primaria. Madrid: Sociedad Española de Cardiología; 1997. p. 17-25.
- Garg R, Yusuf S, for The Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995; 273: 1450-1456.
- Goldberg RJ. Assessing the population burden from heart failure. Arch Intern Med 1999; 159:15-17.
- González-Juanatey JR, Vallés F. Antagonistas de los receptores angiotensina II en la insuficiencia cardíaca. Med Clin (Madrid) 2000; 114 (Supl 1): 43-45.
- Hampton JR, van Veldhuisen DJ, Kleber FX, Cowley AJ, Ardia A, Block P et al for the Second Prospective Randomised study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators. Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Lancet 1997: 349: 971-977.
- Iriarte M, Murga N, Sagastagoitia D, Molinero E, Morillas M, Salcedo A et al. Congestive Heart failure from left ventricular dysfunction in systemic hypertension. Am J Cardiol 1993; 71: 308-312.
- Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997; 157: 2413-2446.
- Kannel WB, Belanger AJ. Epidemiology of heart failure. Am Heart J 1991; 121: 951-957.
- Konstan M, Dracup K, Baker D, Bottorf MB, Brooks NH, Dacey RA et al. Heart failure: evaluation and care of patients with left ventricular systolic disfunction. Clinical practice guideline nº 11. AHCPR publication nº 94-0612. Rockville, MD: Agency for Health Care Policy and Research, Public Health Service, US Department of Health and Human Services, june of 1994.
- Likoff MJ, Chandler SL, Kay HR. Clinical determinants of mortality in chronic congestive heart failure secondary to idiopathic dilated or to ischaemic cardiomyopathy. Am J Cardiol 1987; 59: 634-638.
- Llisterri JL, Rodríguez G, Alonso FJ, Rodríguez L, Barrios V. La insuficiencia cardíaca congestiva en atención primaria (I). Concepto, clasificación, epidemiología, etiología, fisiopatología, pronóstico, diagnóstico y complicaciones. SEMERGEN 2000; 26 (1): 5-13.
- Llisterri JL, Rodríguez GC. Detección y manejo de la insuficiencia cardíaca en Atención Primaria. Cardiol Extrahosp 1999; 5: 39-44.
- Lobos JM, Conthe P, Villegas M, Jubete MT, Sánchez M. Chronic heart failure: a multicenter study in Spain from primary care. Eur J Heart Failure 1999; 1: 18.
- Lobos JM. Papel del médico de familia en la evaluación clínica de la insuficiencia cardíaca. En: Ruiz de Adana Ed. Libro del año de medicina familiar y comunitaria. Madrid: Saned; 1996. p. 90-106.
- López-Rodríguez I, Castro-Beiras A, Asensi A, Bacariza F, Rábade JM, Muñiz J. Normas básicas de manejo de la insuficiencia cardíaca en atención primaria. Aten Primaria 1999; 24: 289-294.
- Mckee P, Castelli WP, McNamara PM et al. The natural history of congestive heart failure: The Framingham study. N Eng J Med 1971; 26: 1441-1446.
- McKelvie RS, Yusuf S, Pericak D, Avezum A, Burns RJ, Probstfield J et al, for the RESOLVD Pilot Study Investigators. Comparison of Candesartan, Enalapril, and Their Combination in Congestive Heart Failure. Randomised Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study. Circulation 1999; 100: 1056-1064.
- MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353: 2001-2007.
- Navarro-López F, de Teresa E, López-Sendón JL, Castro-Beiras A. Guías del diagnóstico, clasificación y tratamiento de la insuficiencia cardíaca y del shock cardiogénico. Informe del Grupo de Trabajo de Insuficiencia Cardíaca de la Sociedad Española de Cardiología. Rev Esp Cardiol 1999; 52 Supl 2: 1-54.
- O´Connell JB, Bristow MR. Economic impact of heart failure in the Unites States: time for a different approach. J Heart Lung Transplant 1994; 13 (4): S107-S112.
- Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler M, Gilbert E et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Eng J Med 1996; 334: 1349-1355.
- Packer M, Carver JR, Rodenheffer RJ. Effect oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1991; 325: 1468-1475.
- Packer M, Medina N, Yushak M. Hemodynamic and clinical limitations of long term inotropic therapy with amrinone in patients with severe heart failure. Circulation 1984; 70: 1038-1047.
- Packer M, Poole-Wilson P, Armstrong P, Cleland J, Horowitz J, Massie B et al, on behalf of the ATLAS Study Group. Comparative Effects of Low Doses and High Doses of the Angiotensin Converting-Enzyme Inhibitor, Lisinopril, on Morbidity and Mortality in Chronic Heart Failure. Circulation 1999; 100: 2312-2318.
- Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K et al. on behalf of the ELITE II investigators. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582-1587.
- Plaza L. Estimulación neuroendocrina. Efectos adversos de la estimulación simpática. Rev Esp Cardiol 1997; 50 Supl 3: 23-29.
- Rodríguez G, Llisterri JL, Alonso FJ, Barrios V, Rodríguez L. La insuficiencia cardíaca congestiva en atención primaria (y II). Tratamiento, criterios de derivación y seguimiento.SEMERGEN 2000; 26 (2): 66-76.
- Rodríguez GC, Llisterri JL. La insuficiencia cardíaca congestiva crónica: Avances en el conocimiento de su fisiopatología y abordaje clínico en Atención Primaria. FOMECO 2001; 9: 8-19.
- Rodríguez GC, Llisterri JL. La insuficiencia cardíaca congestiva crónica: Abordaje terapéutico en Atención Primaria. FOMECO 2001; 9: 68-80.
- Rodríguez GC, Rodríguez L. Jueves Cardiológicos SEMERGEN (Plan Nacional de Formación Continuada SEMERGEN-CARDIOLOGÍA). Madrid: Jarpyo Editores; 1997. p. 43-49.
- Steering Committee and Membership of the Advisory Council to Improve Outcomes Nationwide in Heart Failure. Consensus recommendations for the Management of Chronic Heart Failure. Am J Cardiol, 1999; 83 (2 A): 1 A-38 A.
-- Swedberg K, Pfeffer M, Granger C, Held P, McMurray J, Ohlin G et al, for the CHARM-programme investigators. Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity (CHARM): Rationale and Design. J Card Fail 1999; 5: 276-282.
- Tecce MA, Pennington JA, Segal BL, Jessup ML. Heart failure: clinical implications of systolic and diastolic dysfunction. Geriatrics 1999; 54: 24-33.
- The BEST Steering Committee. Design of the Beta-Blocker Evaluation Survival Trial (BEST). Am J Cardiol 1995; 75: 1220-1223.
- The CAPRICORN Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001; 357: 1385-1390.
- The Captopril-Digoxin Multicenter Research Group. Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. JAMA 1988; 259: 539-544.
- The CONSENSUS Trial Study Group. Effect of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1.429-1.435.
- The Criteria Committee of the New York Heart Association. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels. 9ª ed. Boston: Little, Brown & Co; 1994. p. 253-256.
- The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336: 525-533.
- The SOLVD Investigators. Effect of enalapril on mortality and the development of heart in asymptomatic patients with reduced left ventricular ejection (SOLVD II). N Engl J Med 1992; 327 (10): 685-691.
- The SOLVD Investigators. Effects of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure (SOLVD I). N Engl J Med 1991; 325: 293-302.
- The Task Force for the Diagnosis and Treatment of Chronic Heart Failure, European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001; 22:1527-1560.
- Velasco JA, Maureira JJ. Rehabilitación del paciente cardíaco. Barcelona: Ediciones Doyma, 1993.

 

 


| Sumario